Vertex Pharmaceuticals stock gains as inaxaplin data advance

Published on 09/22/2026 at 17:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Vertex Pharmaceuticals stock traded at USD 510.72 on September 22, 2026, with a USD 129.62 billion market cap. Q2 revenue reached USD 3.33 billion.

Bauhaus-Poster mit geometrischen Formen, Molekülsymbol und großem Schriftzug PHARMA — Vertex Pharma US92532F1003 zeigt ein geometrisches Bauhaus-Poster mit Sektor-Text PHARMA und stilisierter Molekülgrafik, Illustration mit AI erstellt.

Vertex Pharmaceuticals Incorporated (ISIN US92532F1003) traded at USD 510.72 on Nasdaq on September 22, 2026, while the company reported positive Phase 2b results for inaxaplin in APOL1-mediated kidney disease. The trial included 41 participants and completed enrollment in the Phase 2/3 AMPLITUDE study.

Inaxaplin delivers measurable reductions

According to Business Wire on September 22, 2026, the 23-person cohort with APOL1-mediated kidney disease and modest proteinuria recorded a 42.7 percent reduction in urine albumin to creatinine ratio at Week 13 versus baseline. The urine protein to creatinine ratio declined 44.7 percent in the same cohort.

In the second cohort, which included 18 people with APOL1-mediated kidney disease and type 2 diabetes, the urine albumin to creatinine ratio fell 17.3 percent at Week 13 versus baseline. The trial used a 45 mg once-daily dose, and the most common adverse event was headache at 7.3 percent.

AMPLITUDE sets the next milestone

Investing.com reported on September 22, 2026, that Vertex had completed enrollment in the Phase 2/3 AMPLITUDE trial. The company plans an interim analysis in early 2027 after the relevant cohort reaches 48 weeks of treatment, creating a dated development milestone beyond the current study.

The clinical signal is not uniform across the two cohorts: the 42.7 percent reduction in the modest-proteinuria group was 25.4 percentage points larger than the 17.3 percent reduction in the diabetes cohort. That gap makes the patient population and trial design important variables for the next data release.

Stock remains below yearly high

Vertex stock stood at USD 510.72 on September 22, 2026, up 0.47 percent on the day in MarketBeat data. The same snapshot put the 52-week range at USD 374.17 to USD 560.25, market capitalization at USD 129.62 billion and trading volume at 905,468 shares.

For valuation context, Investing.com reported on September 22, 2026, that Stifel reiterated a Hold rating and a USD 500.00 price target. MarketBeat listed a consensus Moderate Buy rating and an average target of USD 573.83, or 12.36 percent above the quoted price.

Vertex stock trades at USD 510.72

Vertex Pharmaceuticals stock traded at USD 510.72 on Nasdaq as of September 22, 2026. The next scheduled quarterly reporting date listed by MarketBeat is November 2, 2026.